**FOI Ref: 6615**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Medicines in Dermatology**

**Date Received: 20/09/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I have a freedom of information query regarding the use of Biologic medicines in Dermatology.  Could you please answer the following two questions: | |
| 1. How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:  * Abatacept * Adalimumab - Humira * Adalimumab Biosimilar * Apremilast * Bimekizumab * Brodalumab * Certolizumab * Dimethyl fumarate * Etanercept - Enbrel * Etanercept Biosimilar * Golimumab * Guselkumab * Infliximab - Remicade * Infliximab Biosimilar * Ixekizumab * Risankizumab * Secukinumab * Tildrakizumab * Tofacitinib * Ustekinumab * Upadacitinib | * Abatacept – 0 * Adalimumab – Humira – 0 * Adalimumab Biosimilar – 32 * Apremilast – 0 * Bimekizumab – 0 * Brodalumab – 2 * Certolizumab – 3 * Dimethyl fumarate – 2 * Etanercept – Enbrel – 0 * Etanercept Biosimilar – 0 * Golimumab – 0 * Guselkumab – 29 * Infliximab – Remicade – 0 * Infliximab Biosimilar – 0 * Ixekizumab – 3 * Risankizumab – 13 * Secukinumab – 25 * Tildrakizumab – 0 * Tofacitinib – 0 * Ustekinumab – 34 * Upadacitinib – 0 |
| 1. How many patients were treated in the last 3 months by the **Dermatology** department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs:  * Adalimumab - Humira * Adalimumab Biosimilar * Apremilast * Certolizumab * Dimethyl fumarate * Etanercept - Enbrel * Etanercept Biosimilar * Guselkumab * Infliximab - Remicade * Infliximab Biosimilar * Ixekizumab * Risankizumab * Secukinumab * Ustekinumab | We don’t keep data of psoriatic arthritis only so are unable to provide data for this. |